# A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression

> **NCT03423680** · PHASE3 · RECRUITING · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 390 (estimated)

## Conditions studied

- Depression, Bipolar

## Interventions

- **DRUG:** Abilify 2, 5, 10, 15mg (Tablet)
- **DRUG:** Placebo of Abilify 2, 5, 10, 15mg (Tablet)

## Key facts

- **NCT ID:** NCT03423680
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-02-22
- **Primary completion:** 2025-11
- **Final completion:** 2025-12
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03423680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03423680, "A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03423680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*